What is the appropriate management for a 2.6 cm left adrenal incidentaloma?

Management of a 2.6 cm Left Adrenal Nodule

A 2.6 cm adrenal incidentaloma requires comprehensive hormonal evaluation followed by imaging surveillance, with surgery reserved only if the mass is hormonally active or demonstrates concerning radiological features.

Initial Evaluation Framework

Hormonal Assessment (Required for All Patients)

All patients with adrenal incidentalomas must undergo biochemical screening to exclude hormone hypersecretion 1, 2. At 2.6 cm, this lesion falls below the 4 cm threshold where size alone would mandate surgery, making functional status the primary determinant of management.

Required hormonal tests include:

• 1-mg overnight dexamethasone suppression test (preferred screening for autonomous cortisol secretion) - cortisol >5.0 µg/dL suggests subclinical Cushing's syndrome (SCS) 1, 2
• Plasma free metanephrines and normetanephrines OR 24-hour urinary metanephrines to exclude pheochromocytoma 1, 2
• Plasma aldosterone concentration/plasma renin activity (PAC/PRA) ratio if the patient has hypertension or hypokalemia 2

Radiological Characterization

If not already performed, obtain non-contrast CT to measure Hounsfield units (HU) 1, 2. This is critical for risk stratification:

• <10 HU: Benign adenoma (traditional threshold) 1
• 10-20 HU: Indeterminate, low malignancy risk (~0.5%) 3
• >20 HU: Suspicious, requires further evaluation 3

Recent evidence suggests that lesions <4 cm with <20 HU can be considered benign in true incidentalomas 4, though the 2023 CUA/AUA guidelines still recommend second-line imaging (washout CT or chemical shift MRI) for masses >10 HU 2.

Management Algorithm Based on Results

If Hormonally Active → Surgery

Proceed with adrenalectomy (preferably minimally invasive) if any of the following are present 1, 2:

• Overt Cushing's syndrome with clinical stigmata
• Pheochromocytoma (requires preoperative α-blockade) 1
• Primary aldosteronism (after adrenal vein sampling confirmation) 2

For subclinical Cushing's syndrome (SCS): Surgery is controversial but should be considered in younger patients with progressive metabolic comorbidities (hypertension, diabetes, dyslipidemia, osteoporosis) attributable to cortisol excess after shared decision-making 1, 2. Recent evidence supports expanded surgical indications in carefully selected SCS patients with documented comorbidities 3.

If Non-Functional and Radiologically Benign → Surveillance

For non-functional lesions <4 cm with benign imaging characteristics (<10 HU):

• Repeat imaging at 6-12 months, then annually for 1-2 years 1, 2
• Repeat hormonal evaluation annually for up to 5 years 1
• The risk of developing hormonal activity is 17% at 1 year, 29% at 2 years, and 47% at 5 years 1

Indications to reconsider surgery during surveillance:

• Growth >1 cm (or >5 mm/year per newer guidelines) 1, 2
• Development of hormonal activity 1
• Lesions growing <3 mm/year require no further follow-up 2

If Indeterminate Features → Individualized Approach

For lesions with indeterminate imaging (10-20 HU) that are non-functional, management options include 2:

• Repeat imaging in 3-6 months
• Surgical resection (based on patient age, comorbidities, and preference)

Critical Pitfalls to Avoid

1. Never biopsy an adrenal mass without first excluding pheochromocytoma - this can precipitate hypertensive crisis 2

2. Do not rely solely on size - a 2.6 cm mass can still be a pheochromocytoma or functioning adenoma requiring surgery 1

3. Washout CT has limitations - approximately 1/3 of pheochromocytomas may washout like adenomas, and 1/3 of adenomas don't washout in the adenoma range 2. Some recent evidence questions its continued utility 4

4. Post-operative management - If surgery is performed for cortisol-producing lesions (including SCS), patients require glucocorticoid replacement for 6-18 months until HPA axis recovery 1

Practical Summary for This Case

For this 2.6 cm left adrenal nodule:

1. Obtain hormonal workup immediately (dexamethasone suppression test, metanephrines, PAC/PRA if hypertensive)
2. Review imaging for HU density on non-contrast CT
3. If non-functional and <10 HU: Surveillance with repeat CT at 6-12 months and annual hormonal testing
4. If hormonally active: Refer for surgical evaluation
5. If indeterminate imaging (>10 HU): Consider second-line imaging or closer surveillance based on clinical context

The overwhelming likelihood is that this represents a benign, non-functional adenoma requiring only surveillance, but systematic evaluation is mandatory to identify the minority requiring intervention 5, 6, 7.